Stock Insider Trading (from SEC Form 4)

ATRS / Antares Pharma, Inc. insiders include Deerfield Mgmt L.P. (), APPLE ROBERT F (President & CEO), Stacey Jennifer Evans (SVP, General Counsel & Secty), JACOB LEONARD S, and DEERFIELD MANAGEMENT CO (), ROCHE ROBERT P JR, GARRITY THOMAS J Powell Fred M (Senior Vice President & CFO), Fickenscher James E (Senior Vice President & CFO), Deerfield International Master Fund, L.P. (), GRAHAM PETER J (SVP General Counsel, Secretary), Deerfield Special Situations Fund, L.P. (), HOBBS EAMONN P (President & CEO), GONELLA JACQUES, SAMSON MARVIN, Flynn James E (), DEERFIELD PARTNERS, L.P. (), GUETH ANTON, .

Antares Pharma, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
Latest
File Date
Latest
Tran Date
Insider Code Shares Post Shares Percent
Change
Share
Price
Tran Value Post Value Percent
Change
2017-10-11 2017-10-09 JACOB LEONARD S Director
S -200,000 207,485 -49.08 4.0521 -810,420 840,750 -96.39
2017-10-05 2017-10-03 GARRITY THOMAS J Director
S -30,000 160,213 -15.77 3.50 -105,000 560,746 -18.73
2017-06-13 2017-06-09 Powell Fred M Senior Vice President & CFO
P 130,000 331,434 64.54 2.7944 363,272 926,159 39.22
2017-06-09 2017-06-07 APPLE ROBERT F President & CEO, Director
A -338,115 1,175,637 -22.34 2.66 -899,386
2017-06-09 2017-06-07 GRAHAM PETER J SVP General Counsel, Secretary
A 101,434 225,851 81.53 2.66 269,814
2017-04-12 2017-04-10 SAMSON MARVIN Director
G -50,000 52,778 -48.65 2.80 -140,000
2017-04-04 2017-03-31 GONELLA JACQUES Director
M 30,000 12,056,413 0.25 1.65 49,500
2016-06-06 2016-06-02 Fickenscher James E Senior Vice President & CFO
A 121,050 391,266 44.80 1.12 135,576
2016-03-22 2016-03-18 ROCHE ROBERT P JR Director
P 50,000 88,172 130.99 0.72 36,000 63,484 56.71
2016-03-21 2016-03-18 GUETH ANTON Director
P 50,000 302,776 19.78 0.72 36,000 217,999 16.51
2015-09-30 2015-09-30 Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
DEERFIELD MANAGEMENT CO 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
Deerfield Special Situations Fund, L.P. 10% Owner
S -83,930 5,348,776 -1.54 1.6921 -142,018 9,050,664 -1.57
2015-07-22 2015-06-22 HOBBS EAMONN P President & CEO, Director
F -9,264 435,990 -2.08 2.41 -22,326
2015-06-01 2015-05-28 Stacey Jennifer Evans SVP, General Counsel & Secty
A 70,239 92,042 322.15
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

ATRS : Antares Pharma Stock Analysis and Research Report

Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...

Click for full article

Related News Stories

Biotech Forum Daily Digest For January 16th

2018-02-16 seekingalpha
The market has staged a huge bounce-back rally this week after two weeks of brutal declines. (126-3)

Why AMAG Pharmaceuticals, Inc. (AMAG) Shares Are Skyrocketing Today

2018-02-16 investorplace
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are skyrocketing Thursday as the company received regulatory approval for one of its treatments. (45-0)

Why AMAG Pharmaceuticals Is Soaring

2018-02-15 247wallst
AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) saw its shares skyrocket early on Thursday after the company announced that it received an FDA approval. Specifically, the company said that the FDA approved its supplemental New Drug Application (NDA) for Makena, which was designed as a treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who spontaneously delivered one preterm baby in the past. (45-0)

Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector - MarketWatch

2018-02-15 marketwatch
Shares of Antares Pharma Inc. ATRS, -1.49% and Amag Pharmaceuticals AMAG, +1.46% soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector drug-device combination product, a ready-to-administer treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who spontaneously delivered one preterm baby in the past. (34-0)

Cumberland Pharmaceuticals: No Reason To Turn Bullish After Q3

2018-01-22 seekingalpha
But the company is buying those revenues: earnings are down, and the legacy portfolio is collapsing. (35-1)

FDA CRL Letters: More Transparency Is Better - Bloomberg

2018-01-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (50-0)

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

3 Biotechs For The January Effect

2018-01-03 seekingalpha
In my view, three biotech microcaps may yield among the best risk/reward scenarios for investors today. (182-5)

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

2017-11-27 accesswire
NEW YORK, NY / ACCESSWIRE / November 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. (34-1)

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 - ATRS

2017-11-27 accesswire
NEW YORK, NY / ACCESSWIRE / November 27, 2017, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: (34-1)